Cargando…
Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials
The treatment of malignant melanoma has drastically changed over the past decade with the advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and other novel therapies such as oncolytic virus intralesional therapy. Despite improvements in patient response rates and survi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894940/ https://www.ncbi.nlm.nih.gov/pubmed/35251322 http://dx.doi.org/10.1177/17588359221083052 |